|Massive hemothorax following administration of intrapleural streptokinase.|
|Jump to Full Text|
|PMID: 21760848 Owner: NLM Status: In-Data-Review|
|The administration of intrapleural streptokinase (IPSK) is widely practiced in the management of loculated empyema thoracis. To our knowledge, there have been only 4 cases of hemorrhagic complications attributed to the administration of IPSK reported in the literature. In this article, we report a case of a 17-year-old girl who received IPSK and developed shock, anemia, coagulopathy and massive hemothorax. Our discussion focuses on the hemorrhagic complication of chest tube insertion and the role of IPSK in blood clot lysis and inhibition of local hemostasis.|
|Feng Yih Chai; Yeh Chunn Kuan|
Related Documents :
|17083578 - Bacterial pseudomycetoma in dwarf hamster, phodopus sungorus.
1111428 - Demoplastic fibroma of the mandible. a case report.
18299218 - Peripheral ameloblastic fibroma of the maxilla: report of a case and review of the lite...
19930688 - Desmoplastic fibroma of the mandible--review of the literature and presentation of a ra...
21798008 - Quantitative radiologic criteria for the diagnosis of lumbar spinal stenosis: a systema...
12519108 - Danish gynecologists' opinion about hysterectomy on benign indication: results of a sur...
|Type: Journal Article|
|Title: Annals of thoracic medicine Volume: 6 ISSN: 1998-3557 ISO Abbreviation: Ann Thorac Med Publication Date: 2011 Jul|
|Created Date: 2011-07-15 Completed Date: - Revised Date: -|
Medline Journal Info:
|Nlm Unique ID: 101280721 Medline TA: Ann Thorac Med Country: India|
|Languages: eng Pagination: 149-51 Citation Subset: -|
|Department of Surgery, Faculty of Medicine, Universiti Kebangsaan, Kuala Lampur, Malaysia.|
|APA/MLA Format Download EndNote Download BibTex|
Journal ID (nlm-ta): Ann Thorac Med
Journal ID (publisher-id): ATM
Publisher: Medknow Publications, India
Copyright: © Annals of Thoracic Medicine
Received Day: 28 Month: 1 Year: 2011
Accepted Day: 30 Month: 3 Year: 2011
Print publication date: Season: Jul-Sep Year: 2011
Volume: 6 Issue: 3
First Page: 149 Last Page: 151
PubMed Id: 21760848
Publisher Id: ATM-6-149
|Massive hemothorax following administration of intrapleural streptokinase|
|Feng Yih Chaiaff1|
|Yeh Chunn Kuan1|
Department of Surgery, Faculty of Medicine, Universiti Kebangsaan, Kuala Lampur, Malaysia
1Department of Internal Medicine, Faculty of Medicine, International Islamic University of Malaysia, Kuala Lampur, Malaysia
|Correspondence: Address for correspondence: Dr. Feng Yih Chai, Department of Surgery, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. E-mail: firstname.lastname@example.org
Intrapleural streptokinase (IPSK) administration in loculated empyema thoracis may improve its drainage by breaking down the fibrinous septations.[1, 2] Despite contradicting data on safety and efficacy of IPSK, it is practiced widely.[2, 3] Here, we report a case of severe intrapleural hemorrhage after the administration of IPSK and discuss other possible causes of the bleeding.
A 17-year-old girl was admitted with 3 weeks of fever, productive cough and right pleuritic chest pain. On presentation, her respiratory rate was 28 breaths/minute, blood pressure was 87/52 mm Hg, heart rate was 140 beats/minute, temperature was 39.5°C and oxygen saturation was 96% in room air. There were crepitations bilaterally and reduced breath sounds at the right lower hemithorax with stony dullness on percussion. Her investigations showed that her hemoglobin was 9.0 g/dL, platelet count was 386,000/μL, white blood cell count was 12,140/μL (predominantly neutrophils) and coagulation profile was normal. Her chest radiograph [Figure 1] showed a large right loculated pleural effusion. A 28-French chest tube was inserted, and a total of 1.2 L of pus was drained. She was diagnosed with right loculated empyema thoracis and started on intravenous co-amoxiclav 1.2 g three times a day. Two days later, her vital signs returned to normal.
On day 3 of admission, the chest tube was replaced because it was blocked. However, chest tube drainage remained poor despite persistent pleural effusion on chest radiograph [Figure 2]. When regular flushing with normal saline failed to improve chest tube drainage, the patient was started on intrapleural streptokinase 250,000 units, 12 hourly.
After 3 doses of IPSK, the patient complained of palpitations, sweating and giddiness and had a respiratory rate of 25 breaths/minute, blood pressure of 70/50 mm Hg, pulse rate of 140 beats/minute and temperature of 38.3°C. Her blood investigations showed that her hemoglobin had dropped to 6.5 g/dL with a platelet count of 209,000/μL and white cell count of 18,600/μL. Her International Normalized Ratio was 1.5, but her activated partial thromboplastin time was normal. Chest radiograph was repeated [Figure 3], which showed that her right hemithorax was completely opaque, but her chest tube continued to drain only 100 mL of sanguineous fluid daily. She was diagnosed with a right massive hemothorax.
An immediate thoracic surgical consult was sought. However, the patient was too unstable for transport to the nearest cardiothoracic surgical center, which was 250 km away. We were advised to promptly resuscitate and stabilize the patient at our intensive care unit. Her chest tube was blocked and was replaced again. The new chest tube drained 1.1 L of altered blood over the next 2 days. A total of 7 units of packed red blood cells were transfused to restore her hemodynamic status. Her hemoglobin level was 9.6 g/dL post-transfusion, and her coagulation profile normalized. After 14 days of intensive care, she was then transferred to the cardiothoracic center, where she underwent right lung decortications and recovered uneventfully.
Despite advancement in technology and the availability of more efficacious antibiotics, empyema thoracis still requires drainage. Our patient had her chest tube inserted unassisted by imaging within 24 hours of admission and drained 1.2 L of pus. Ideally, ultrasonography or computed tomography prior to chest tube insertion should be used to locate the most suitable chest tube entry site for drainage of loculated empyema. It can prevent complications and may improve outcome.
Hemorrhagic complication after IPSK administration is rare. To our knowledge, there have been only 4 cases of hemorrhagic complications attributed to the administration of IPSK reported in the literature.[2, 5, 6] Our patient was given 3 doses of IPSK (250,000 IU, 12 hourly) before she developed anemia, shock and coagulopathy. Her condition could have resulted from massive intrapleural hemorrhage due to traumatic chest tube insertion. On the other hand, in the presence of leukocytosis and fever, sepsis could have complicated her shock and coagulopathy.
The usage of IPSK as intrapleural fibrinolytic therapy is debatable. Its usage is considered safe and has not been shown to activate systemic fibrinolytic activity. However, given the immunogenicity of streptokinase and its inability to reduce pus viscosity, there has been increasing interest in tissue plasminogen activator (tPA) and recombinant human deoxyribonuclease (DNase) as better alternatives to facilitate drainage of empyema thoracis. tPA induces fibrinolysis by preferentially activating plasminogen bound to fibrin and is less immunogenic, whereas DNase reduces pus viscosity by fragmenting free uncoiled deoxyribonucleic acid found in pus.[1, 8] A multicentered randomized trial by Rahman et al. has shown that combination of tPA and DNase was significantly superior to using either tPA or DNase alone in improving pleural fluid drainage.
The complication rate of chest tube insertion is reported as high as 30%, with hemorrhagic complication ranging from 3.0% to 7.8%.[1, 10] Hemorrhage from chest tube insertion can be caused by injured intercostal vessels or by lung parenchyma. Our patient's second chest tube insertion was uneventful. It was conducted by an experienced medical officer, who encountered minimal external blood loss. A subsequent computed tomography of the thorax showed that the chest tube was placed appropriately without causing any active bleeding from the chest wall. However, small lung parenchymal injury could not be ruled out on the basis of the scan. The lung parenchyma could be injured during the instrumentation and later concealed by blood clots. Consequently, no major bleeding was seen through the chest tube drainage.
Temes et al. reported a case of a patient who developed hemothorax following administration of IPSK for empyema thoracis. During the emergency thoracotomy, the hemorrhage was found to have originated from a rib fracture sustained 1 month prior to administration of IPSK. Streptokinase is a potent fibrinolytic agent. It binds and activates human plasminogen to produce plasmin. Subsequently, plasmin breaks down fibrin, which is a major constituent of a blood clot, and dissolves the clot. Therefore, it is possible that the administered IPSK had dissolved the formed blood clot at our patient's traumatized lung parenchyma, inhibited local hemostasis and caused hemorrhage.
In conclusion, administration of IPSK may cause rare but life-threatening intrapleural hemorrhage. Its potent fibrinolytic activity lyses not only the fibrinous septations in loculated empyema thoracis but also possibly the blood clot covering a traumatized area and inhibits local hemostasis.
Source of Support: Nil
Conflict of Interest: None declared.
|1.||Maskell NA,Davies CW,Nunn AJ,Hedley EL,Gleeson FV,Miller R,et al. UK controlled trial of intrapleural streptokinase for pleural infectionN Engl J MedYear: 20053528657415745977|
|2.||Temes RT,Follis F,Kessler RM,Pett SB Jr,Wernly JA. Intrapleural fibrinolytics in management of empyema thoracisChestYear: 199611010268681611|
|3.||Cameron RJ,Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyemaCochrane Database Syst RevYear: 20082CD00231218425881|
|4.||Davies CW,Gleeson FV,Davies RJ. BTS guidelines for the management of pleural infectionThoraxYear: 200358ii182812728147|
|5.||Laisaar T,Püttsepp E,Laisaar V. Early administration of intrapleural streptokinase in the treatment of multiloculated pleural effusions and pleural empyemasThorac Cardiovasc SurgYear: 19964425268948554|
|6.||Godley PJ,Bell RC. Major haemothorax following administration of intrapleural streptokinaseChestYear: 19848648676468013|
|7.||Davies CW,Lok S,Davies RJ. The systemic fibrinolytic activity of intrapleural streptokinaseAm J Respir Crit Care MedYear: 1998157328309445316|
|8.||Simpson G,Roomes D,Heron M. Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pusChestYear: 200011717283310858409|
|9.||Rahman NM,Maskell N,Davies CW,West A,Teoh R,Arnold A,et al. Primary result of the second multicentre intrapleural sepsis (MIST2) trial; randomized trial of intrapleural tPA and DNase in pleural infectionThoraxYear: 200964A119952167|
|10.||Ball CG,Lord J,Laupland KB,Gmora S,Mulloy RH,Ng AK,et al. Chest tube complications: How well are we training our residents?Can J SurgYear: 200750450818053373|
Keywords: Coagulopathy, complications, hemothorax, streptokinase, thoracic empyema.
Previous Document: Refractory recurrent bleeding as a late mortal complication of chest wall irradiation.
Next Document: Progesterone Receptor-B Induction of BIRC3 Protects Endometrial Cancer Cells from AP1-59-Mediated Ap...